Abstract
Patient-reported outcomes (PROs) are an increasingly important aspect of patient care, as they offer a perspective from the patient themselves in the treatment and management of a particular disease state. They have a potential role in helping clinicians select an appropriate drug regimen in human immunodeficiency virus-1 (HIV-1)-infected individuals, as well as those with HIV/hepatitis C (HCV) co-infection. They can also provide insight for individuals receiving long-acting (LA) injectable antiretroviral therapy (ART). Studies found from PROs that participants on an LA injectable ART regimen reported greater preference and treatment satisfaction compared with those on an oral ART regimen. Some additional studies have also used PROs to evaluate the switch to single-tablet regimens and compare different ART in treating HIV-1. Current PROs and how they can be improved for LA injectables were also discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 543-553 |
| Number of pages | 11 |
| Journal | Future Virology |
| Volume | 16 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2021 |
Keywords
- HIV
- antiretroviral
- long-acting injectables
- patient reported outcomes
Fingerprint
Dive into the research topics of 'Patient-reported outcomes for HIV: The future of long-acting injectables and antiretroviral therapy evaluations'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver